PDCD1 and gastric cancer: For the clinical trial with immunotherapy, literature demonstrated that avelumab (anti-PD-1) has anti-tumor activity and is safe for patients with GC, which is administered as maintenance therapy (after the disease is under control with standard chemotherapy) (56).